ArticleACS omega2025
Folic Acid-Chitosan Conjugated Mesoporous Silica Nanoparticles for Enhanced Piceatannol Uptake in MCF‑7 Breast Cancer Cells.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Smart Mesoporous Silica Nanoparticle-Based Drug Delivery Systems: Recent Advances in Biomedical Applications, Wound Healing and Therapeutic Perspectives.Pharmaceutics · 2026Review
- Folic Acid-Guided PLGA-Zein Core-Shell Nanoparticles for Co-Delivery of Temozolomide and Ellagic Acid to Overcome PARP-Mediated Chemoresistance in Glioblastoma.Pharmaceutics · 2026Article
- Mesoporous silica nanoparticles functionalized with folic acid and zinc for enhanced targeted delivery of daunorubicin to breast cancer cells.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted drug delivery using nanoparticle-based systems offers a promising strategy for improving breast cancer therapy. Mesoporous silica nanoparticles (MSNs) are attractive carriers due to their stability and ease of surface modification for attaching targeting ligands like folic acid. This study developed a folate receptor-mediated delivery system using functionalized MSNs loaded with piceatannol (PTL), a natural compound with known anticancer potential. MSNs were functionalized with 3-aminopropyltriethoxysilane (APTES) and succinic anhydride and then conjugated with a folic acid-chitosan (FA-CS) conjugate. This functionalization significantly enhanced not only PTL loading (44% vs 16% in bare MSNs) but also entrapment efficiency (89% vs 32%). Further, X-ray diffraction confirmed PTL remained amorphous within the MSNs, improving its aqueous solubility. Apart from this, the FA-CS conjugated MSNs demonstrated pH-sensitive, diffusion-controlled PTL release, with significantly higher release at acidic pH (88% at pH 5.5 in 2 h) compared to physiological pH (30% at pH 7.4). Subsequently, in vitro cellular studies on MCF-7 breast cancer cells confirmed a significantly enhanced cytotoxic and apoptotic effect with FA-CS conjugated PTL-loaded MSNs. This improved efficacy is attributed to increased cellular internalization mediated by the folic acid targeting moiety. These findings highlight the potential of FA-CS conjugated MSNs for the development of a targeted and effective delivery system for hydrophobic drugs like PTL for breast cancer treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.